271 related articles for article (PubMed ID: 28859336)
1. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
[TBL] [Abstract][Full Text] [Related]
2. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
[TBL] [Abstract][Full Text] [Related]
3. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
4. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
Zhou J; Zhang C; Pan J; Chen L; Qi ST
Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
[TBL] [Abstract][Full Text] [Related]
5. Proteomics in pediatric cystic craniopharyngioma.
Massimi L; Martelli C; Caldarelli M; Castagnola M; Desiderio C
Brain Pathol; 2017 May; 27(3):370-376. PubMed ID: 28414889
[TBL] [Abstract][Full Text] [Related]
6. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
[TBL] [Abstract][Full Text] [Related]
9. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
[TBL] [Abstract][Full Text] [Related]
10. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets.
Prince E; Whelan R; Donson A; Staulcup S; Hengartner A; Vijmasi T; Agwu C; Lillehei KO; Foreman NK; Johnston JM; Massimi L; Anderson RCE; Souweidane MM; Naftel RP; Limbrick DD; Grant G; Niazi TN; Dudley R; Kilburn L; Jackson EM; Jallo GI; Ginn K; Smith A; Chern JJ; Lee A; Drapeau A; Krieger MD; Handler MH; Hankinson TC;
Acta Neuropathol Commun; 2020 May; 8(1):68. PubMed ID: 32404202
[TBL] [Abstract][Full Text] [Related]
12. Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: Based on single nucleus RNA-seq and spatial transcriptome profiling.
Chen Y; Liu X; Ainiwan Y; Li M; Pan J; Chen Y; Xiao Z; Wang Z; Xiao X; Tang J; Zeng G; Liang J; Su X; Kungulli R; Fan Y; Lin Q; Liya A; Zheng Y; Chen Z; Xu C; Zhang H; Chen G
Cancer Lett; 2024 Jun; 592():216905. PubMed ID: 38677641
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma.
Yang J; Hou Z; Wang C; Wang H; Zhang H
Cancer Gene Ther; 2018 Oct; 25(9-10):227-239. PubMed ID: 29681617
[TBL] [Abstract][Full Text] [Related]
15. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
[TBL] [Abstract][Full Text] [Related]
16. [Expression pattern of inflammatory cytokines at various inflammatory levels of adamantinomatous craniopharyngioma].
Zhou J; Qi ST; Chen LG; Huang CR; You J; Zhang C; Pan J
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2499-501. PubMed ID: 24300275
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1α leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis.
Mao J; Qiu B; Mei F; Liu F; Feng Z; Fan J; Nie J; Huang L; Liao X; Wang Z; Zeng J; Weng Z; Zang N; Qi S; Bao Y
Metabolism; 2019 Dec; 101():153998. PubMed ID: 31666193
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
[TBL] [Abstract][Full Text] [Related]
19. Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.
Stache C; Hölsken A; Fahlbusch R; Flitsch J; Schlaffer SM; Buchfelder M; Buslei R
Neuro Oncol; 2014 Jan; 16(2):256-64. PubMed ID: 24305709
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance.
Wang X; Zhao C; Lin J; Liu H; Zeng Q; Chen H; Wang Y; Xu D; Chen W; Xu M; Zhang E; Lin D; Lin Z
Chin Med J (Engl); 2024 Apr; 137(7):859-870. PubMed ID: 37565822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
